GOGeorge Dennis Obeng

George Dennis Obeng

*This is an algorithmically generated author record based on publicly available information.

George Dennis Obeng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey

    by Kristóf Gyöngyösi, Zsuzsanna Ida Petykó, Dalma Hosszú, Pan Pantziarka, Helene G van der Meer, Donald C Lo, Marcell Csanádi, George Dennis Obeng, Zoltán Kaló, András Inotai

  • Open Access

    Policy barriers to drug repurposing in Europe: different stakeholder perspectives identified during survey-based shortlisting of key challenges

    by Kristóf Gyöngyösi, Zsuzsanna Ida Petykó, Dalma Hosszú, Pan Pantziarka, Helene G. van der Meer, Donald C. Lo, Marcell Csanádi, George Dennis Obeng, Zoltán Kaló, András Inotai


  • Open Access

    Perceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey

    by Kristóf Gyöngyösi, Zsuzsanna Ida Petykó, Dalma Hosszú, Pan Pantziarka, Helene G van der Meer, Donald C Lo, Marcell Csanádi, George Dennis Obeng, Zoltán Kaló, András Inotai

  • Open Access

    Patient Care of Pregnant Women With Chronic Myeloid Leukemia in a Resource Limited Setting—Case Reports From Ghana

    by Amma Benneh-Akwasi Kuma, Leticia Lokko Hanson, Nii Boi-Doku Pepra-Ameyaw, George Dennis Obeng, Marcell Csanádi

    Although life expectancy and survival have improved for CML patients due to the advent of tyrosine kinase inhibitor (TKI) therapies, the quality of life and family planning for women still hold challenges, especially in a resource‐limited setting where routine molecular monitoring and pregnancy‐compatible therapeutic options are limited. Due to their teratogenicity, TKI therapies are generally considered to be contraindicated during pregnancy. Here, we present case reports of three patients from the Korle‐Bu Teaching Hospital in Accra, Ghana, who were diagnosed with CML prior to pregnancy. A 29‐year‐old, 19‐year‐old and 33‐year‐old female were diagnosed with CML at the clinic. All patients initiated imatinib, which was stopped after confirming pregnancy. Patients were subsequently monitored with a monthly full blood count (FBC). While one of the patients was lost to follow‐up, the other two patients delivered without adverse events or fetal abnormalities and were able to restart imatinib therapy within 6 months. Based on the presented cases, a pragmatic framework emerges: (1) embed comprehensive counselling at diagnosis; (2) encourage planned conception only after sustained molecular remission; (3) stop TKIs upon pregnancy confirmation; (4) monitor with clear, communicated thresholds for intervention; (5) introduce cytoreduction after the first trimester only when clinically indicated and consent given; and (6) align postpartum feeding plans with timely TKI re‐initiation. As a conclusion, in contexts where social pressure to bear children is strong and pregnancy‐safe treatments are limited, transparent counselling, a remission‐first strategy, and tightly coordinated hematology–obstetric care offer the best path to balancing reproductive autonomy with maternal and fetal safety.

  • Open Access

    The eyes of the beholder: Perceived barriers to successful drug repurposing

    by Zsuzsanna Ida Petykó, Dalma Hosszú, Marcell Csanádi, Kristóf Gyöngyösi, George Dennis Obeng, David Ameyaw, Tamás István Dóczi, Zoltán Kaló, Donald C. Lo, Helene G. van der Meer, et al.

    Despite tremendous advances in new drug development over recent decades, the medical needs of an ever increasing and ageing global population are still significantly unmet. Drug repurposing (DR)—finding new therapeutic uses for existing medicinal substances and products—offers a promising strategy by potentially reducing development time, costs and risk. However, currently, significant hurdles restrict broader application of DR. This study was conducted within the European Commission funded REMEDi4ALL consortium to systematically identify and analyse the key policy obstacles perceived to be hindering the success of DR. A systematic literature review was conducted using PubMed and Embase, supplemented by grey literature searches and expert interviews within the consortium. The extracted data underwent thematic analysis. A barrier tree was developed and validated through five workshops with 80 experts from seven stakeholder groups. From 4059 hits, 192 were included for data extraction, resulting in the identification of 33 key barriers grouped into nine main themes: perception of off‐patent medicines, business case for on‐patent DR, business case for off‐patent DR, non‐industry‐funded DR, ecosystem for non‐profit or small and medium‐sized enterprise‐driven repurposing, market authorisation, exclusivity rights, health technology assessment and pricing. This comprehensive analysis provides a foundation for prioritizing the main areas for future interventions. Surprisingly, there were considerable differences in how different stakeholders perceived the importance of a number of key barriers. Such multidimensional aspects of DR barriers will need to inform future development of actionable policy recommendations to enhance the DR ecosystem and facilitate broader access to repurposed medicines.


  • Open Access

    Impact of health technology assessment implementation with a special focus on middle-income countries

    by Ahmad Nader Fasseeh, Sarah Maria Saragih, Noha Hayek, Sasha Brodovska, Adham Ismail, Amr ElShalakani, Sherif Abaza, George Dennis Obeng, David Ameyaw, Zoltan Kalo